Must Reads by Date
Must reads for theWeek ending November 11, 2018
PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR
Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454
High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008
RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012
Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018
Must reads for theWeek ending November 4, 2018
Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292
Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514
Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR
Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9
Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD
Must reads for theWeek ending October 28, 2018
Uterine serous carcinoma patients have continuous high risk of VTE , Gressel GM et al. Obstet Gynecol. 2018 Oct 5;132:1130-6.
Prophylactic cranial irradiation boosts OS in advanced NSCLC , Arrieta O et al. WCLC 2018, Abstract MA08.02.
Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.
Targeted therapy with PI3K inhibitor boosts PFS in advanced breast cancer, Andre F et al. ESMO 2018, Abstract LBA3_PR.
Treating prostate with radiotherapy boosts survival in advanced prostate cancer, Parker C et al. ESMO 2018, Abstract LBA5_PR
Must reads for theWeek ending October 21, 2018
Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85
No single genetic driver of metastases in ccRCC, Choueiri TK et al. Br J Cancer. 2018 May;118(9):1238-42.
Staging criteria for RCC with nodal involvement: Time to change?, Karam JA et al. Cancer. 2018 Oct 1. doi: 10.1002/cncr.31661.
RCC incidence rates stabilize while mortality rates drop, Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.
ADT and dementia in prostate cancer, Deka R et al. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4423.
Must reads for theWeek ending October 14, 2018
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32